<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001551891</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001671858</issuerCik>
      <issuerName>ARS Pharmaceuticals, Inc.</issuerName>
      <secFileNumber>001-39756</secFileNumber>
      <issuerAddress>
        <com:street1>11682 EL CAMINO REAL, SUITE 120</com:street1>
        <com:city>SAN DIEGO</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>92130</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>858-771-9307</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Shawver Laura</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>COMMON</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>MERRILL LYNCH</name>
        <address>
          <com:street1>101 S. ELLSWORTH AVE.</com:street1>
          <com:street2>4TH FLOOR</com:street2>
          <com:city>SAN MATEO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94401</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>200000</noOfUnitsSold>
      <aggregateMarketValue>2713000.00</aggregateMarketValue>
      <noOfUnitsOutstanding>97185475</noOfUnitsOutstanding>
      <approxSaleDate>12/02/2024</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>COMMON</securitiesClassTitle>
      <acquiredDate>12/02/2024</acquiredDate>
      <natureOfAcquisitionTransaction>STOCK OPTION AWARD EXERCISE</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>ARS PHARMACEUTICALS, INC.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>97244</amountOfSecuritiesAcquired>
      <paymentDate>12/02/2024</paymentDate>
      <natureOfPayment>CASH</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>COMMON</securitiesClassTitle>
      <acquiredDate>04/29/2020</acquiredDate>
      <natureOfAcquisitionTransaction>STOCK OPTION AWARD EXERCISE</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>ARS PHARMANCEUTICALS, INC.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>102756</amountOfSecuritiesAcquired>
      <paymentDate>04/29/2020</paymentDate>
      <natureOfPayment>CASH UPON EXERCISE</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>The nature of the payment will be cash for the Stock Option Award of 102,756 shares referenced in the Securities to be Sold section upon exercise. </remarks>
    <noticeSignature>
      <noticeDate>12/02/2024</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>10/15/2024</planAdoptionDate>
      </planAdoptionDates>
      <signature>Laura Shawver</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
